Colam Impact

Colam Impact is an impact-investment vehicle with a public footprint that includes LinkedIn and a CB Insights profile, but with limited public disclosure of thesis specifics, fund size, or geographic focus beyond the impact-investment framing. The ‘Colam Impact’ branding signals an impact-driven mandate, presumably targeting companies that generate measurable social or environmental outcomes alongside financial returns. For healthcare AI founders, treat Colam as a likely Latin American or Iberian impact investor whose thesis fit depends on whether your company has a clearly articulated impact narrative — improving access, lowering cost, addressing disparities, or serving underserved populations. Plausible check size is $250K to $2M based on typical impact-fund economics, but specifics warrant confirmation in a first conversation. Stage focus is most plausibly seed through Series A. Founders who should approach: digital health and healthcare-services teams with a credible impact thesis — telemedicine for underserved geographies, mental-health access for low-income populations, public-payer-funded models, and disease-management for chronic conditions in underserved patient populations — particularly those willing to commit to ongoing impact reporting. Founders who should not approach: pure-tech plays without an impact narrative, biotech, and any team unwilling to embed impact KPIs in their reporting. Entry path is warm introduction through the impact-investing network — GIIN, ImpactAssets, Latin American impact investors — or LinkedIn outreach to listed Colam partners. Be prepared with a clear theory of change, quantified impact metrics, and a willingness to sign up to impact reporting commitments. Without an impact narrative, the fit is weak.